Page results
-
Our annual members' meeting (AMM) brings together members, governors and staff, and is where our governors officially receive our annual report and accounts.
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched at UCLH.
-
Information about staff who work in the Macmillan Support and Information Service.
-
This information aims to support and supplement the information provided in the Be Active video available on uclh.nhs.uk/wellbeing
-
Health and wellbeing information for people affected by cancer.
-
This information explains when planned caesareans would be provided at The Whittington Hospital for women having antenatal care at UCLH.
-
Latest news and developments in the Macmillan Support and Information Service
-
Events, classes and workshops at the Macmillan Support and Information Service (MSIS)
-
This information page aims to answer some of the questions you may have about receiving chimeric antigen receptor (CAR) T-cell therapy at University College London Hospitals NHS Foundation Trust (UCLH).
File results
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0545 - Criteria used in determining acceptance of GP referrals for osteoporosis treatment, and for priorisation of osteoporosis appointments
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis